Clinical Trial Update: Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on olaparib (Lynparza) for locally advanced triple-negative breast cancer and locally advanced germline BRCA mutation–positive breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Istituti Ospitalieri di Cremona | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN